Indication intelligence, analysis and sector perception

Kite Pharma (KITE) characterizes of T cell receptor candidates

December 12, 2016 1:09pm

Licensed under the CRADA with the NIH as noted in the New England Journal of Medicine

Share pricing is UP +$1.96 or +4.27% to $47.85 - SELL into strength

KITE announced that characterizations of T cell receptor candidates which it has licensed from NIH have been published in the 12/8/16 New England Journal of Medicine (NEJM).

The research describes a patient with KRAS mutant metastatic colorectal cancer who was successfully treated with T cells that are reactive to KRAS G12D mutation. This work follows previously reported treatment of a patient with advanced cholangiocarcinoma with T cells targeting a mutated erbb2 interacting protein.

The Bottom line: These findings represent proof of concept that T-cell technology directed against neoantigens can be utilized to treat solid tumors.

KITE closed at $45.89 and is UP mid-day +$1.96 or +4.27% - I’d be SELLING into strength … “safety” is my middle name!

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.